盐酸达泊西汀治疗早泄的临床研究进展

Advanced in clinical studies of dapoxetine treatment for premature ejaculation

早泄(PE)是最常见的男性性功能障碍。达泊西汀是一个新型、作用快速的选择性5-羟色胺(5-HT)再摄取抑制剂(SSRIs)。尽管达泊西汀与其他SSRIs有相似的药理作用,但其口服吸收快,半衰期短,排泄快的药动学特征,使其成为适于需时服用治疗PE的药物。临床试验表明,达泊西汀能有效地延长PE患者的阴道内射精的潜伏时间(IELT),改善性功能,且没有严重的不良反应。与传统的SSRIs相比具有更好的安全性和耐受性。本品有可能成为今后改善PE的第一个新药。

premature ejaculation（PE） is the most common sexual dysfunction in men. Dapoxetine is a novel, fast-acting selective serotonin（5-HT） reuptake inhibitor. Although dapoxetine has pharmacological similarities to other selective serotonin reuptake inhibitors（SSRIs） ,its pharmacokinetic properties of rapid-absorbed following oral administration , short half-life and rapid-eliminated make it suitable for on-demand treatment of premature ejaculation（PE）. Clinical studies have shown dapoxetine to be effective in prolonging intravaginal ejaculation latency time （IELT） ,improving sexual function of PE without any major adverse events. It is a safer and more tolerable alternative compared to traditional selective serotonin reuptake inhibitors（SSRIs）.